Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (645)	2/19/1999 10:26:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2001

Just read the new Cowen report (thanks to the person who sent it!). Pretty weak in the area where I needed help, the assessment of indications beyond ADHD where GT 2331 might be used. Also, no thought given to potential flexibility in license negotiations for the molecule. Oesterling et al..... could have sworn that you said, in last week's conference call, that the phase I single-dose would be discussed "next week". That is, it would be discussed this week?